Osteoinductivity potential of rhBMP-2 associated with two carriers in different dosages.
The objective of this study was to evaluate bone formation after application of different doses of recombinant human bone morphogenetic protein-2 (rhBMP-2) combined with monoolein or poloxamer gels, in critical bone defects of rats. Forty-five Wistar rats were divided into nine treatment groups with five animals each: I: application of 1 µg rhBMP-2 + monoolein; II: 3 µg rhBMP-2 + monoolein; III: 7 µg rhBMP-2 + monoolein; IV: 1 µg rhBMP-2 + poloxamer; V: 3 µg rhBMP-2 + poloxamer; VI: 7 µg rhBMP-2 + poloxamer; VII: monoolein only; VIII: poloxamer only; and IX: critical bone defect only. A critical-sized defect of 6 mm diameter was produced in the left parietal bone and it was filled with gels of the above mentioned treatments. After 2 weeks, the calvarial bones were removed for histological processing. Bone formation in the groups that received poloxamer gel and rhBMP-2 was not significantly different from the control group (IX). Groups receiving monoolein and rhBMP-2 (1 and 3 µg) and those that received only the carriers (VII and VIII) had less bone formation in relation to the control. The association of rhBMP-2 to both poloxamer and monoolein did not exhibit any significant differentiation in bone formation in comparison with the control group.
Abdala
Priscilla Maria Fernandes
PM
Department of Morphology, Oral Medicine and Physiology, Faculty of Dentistry, University of São Paulo, Av. Café S/N, Bairro: Monte Alegre, Ribeirão Preto, São Paulo 14040-904, Brazil.
Iyomasa
Mamie Mizusaki
MM
Sato
Sandra
S
Bentley
Maria Vitória Lopes Badra
MV
Pitol
Dimitrius Leonardo
DL
Regalo
Simone Cecílio Hallak
SC
Siéssere
Selma
S
Issa
João Paulo Mardegan
JP
D000818:Animals; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage* / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers / Q000008:administration & dosage* / Q000494:pharmacology*; D005989:Glycerides / Q000008:administration & dosage* / Q000494:pharmacology*; D008297:Male; D010012:Osteogenesis / Q000187:drug effects*; D020442:Poloxamer / Q000008:administration & dosage* / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000494:pharmacology*; D012886:Skull / Q000502:physiology; D016212:Transforming Growth Factor beta / Q000008:administration & dosage* / Q000494:pharmacology*
D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D004337:Drug Carriers; D005989:Glycerides; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D020442:Poloxamer; C005953:monoolein